Individualization of drug therapy in older people

Reviews in Clinical Gerontology

Volumn 24, Issue 2, 2014, Pages 145-157

  Scibona, P ^a   Angriman, F ^a,b   Vazquez, C ^a   Ferreyro, B L ^a,b   Perelsztein, A G ^b   Simonovich, V A ^a   Jauregui, J R ^b   Musso, C G ^b   Belloso, W H ^a,b  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

aged; drug monitoring; drug toxicity; pharmacogenomics; pharmacokinetics; therapeutics

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMANTADINE; ANTIDEPRESSANT AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; CHLORPROPAMIDE; CIPROFLOXACIN; COLCHICINE; COTRIMOXAZOLE; DEXTROPROPOXYPHENE; DONEPEZIL; GABAPENTIN; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMANTINE; METFORMIN; NEUROLEPTIC AGENT; NITROFURANTOIN; PETHIDINE; PRESCRIPTION DRUG; PROBENECID; PROTON PUMP INHIBITOR; RANITIDINE; RIMANTADINE; SEROTONIN TRANSPORTER; SPIRONOLACTONE; TAMOXIFEN; TRIAMTERENE; UNINDEXED DRUG;

DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; DRUG MONITORING; DRUG SENSITIVITY; GERIATRIC CARE; HUMAN; META ANALYSIS (TOPIC); PERSONALIZED MEDICINE; PHARMACOGENOMICS; POLYPHARMACY; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENESCENCE; SYSTEMATIC REVIEW (TOPIC); UNSPECIFIED SIDE EFFECT;

EID: 84896981694     PISSN: 09592598     EISSN: 14699036     Source Type: Journal    
DOI: 10.1017/S0959259814000033     Document Type: Review

References (91)

1. Wooten JM. Pharmacotherapy considerations in elderly adults. South Med J 2012; 105: 437-45
2. Lubitz J, Cai L, Kramarow E, Lentzner H. Health, life expectancy, and health care spending among the elderly. N Engl J Med 2003; 349: 1048-55
3. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004; 56: 163-84
4. Aymanns C, Keller F, Maus S, Hartmann B, Czock D. Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin J Am Soc Nephrol 2010; 5: 314-27
5. Fulop T Jr, Worum I, Csongor J, Foris G, Leovey A. Body composition in elderly people. I. Determination of body composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjects. Gerontology 1985; 31: 6-14
6. Ginsberg G, Hattis D, Russ A, Sonawane B. Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals. Environ Health Perspect 2005; 113: 1243-49
7. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. Br J Clin Pharmacol 2004; 57: 6-14
8. Hutchinson LC. OBC. Changes in pharmacokinetics and pharmacodynamics in the elderly patient. J Pharm Prac 2007; 20: 4-12
9. Zoli M, Magalotti D, Bianchi G, Gueli C, Orlandini C, Grimaldi M et al. Total and functional hepatic blood flow decrease in parallel with ageing. Age Ageing 1999; 28: 29-33
10. Young LL, Lyon CE. Effect of postchill aging and sodium tripolyphosphate on moisture binding properties, color, and Warner-Bratzler shear values of chicken breast meat. Poult Sci 1997; 76: 1587-90
11. Esposito C, Plati A, Mazzullo T, Fasoli G, De Mauri A, Grosjean F et al. Renal function and functional reserve in healthy elderly individuals. J Nephrol 2007; 20: 617-25
12. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278-85
13. Coresh J, Astor B. Decreased kidney function in the elderly: Clinical and preclinical, neither benign. Ann Intern Med 2006; 145: 299-301
14. Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, den Heijer M. Age-And gender-specific reference values of estimated GFR in Caucasians: The Nijmegen Biomedical Study. Kidney Int 2007; 72: 632-37
15. Musso CG, Macias Nunez JF, Oreopoulos DG. Physiological similarities and differences between renal aging and chronic renal disease. J Nephrol 2007; 20: 586-87
16. Perucca E. Age-related changes in pharmacokinetics: Predictability and assessment methods. Int Rev Neurobiol 2007; 81: 183-99
17. Noreddin AM, Haynes V. Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly. Drugs Aging 2007; 24: 275-92
18. Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet 2008; 47: 297-321
19. Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007; 370: 185-91
20. Wang L. Changes in pharmacokinetics in the elderly and therapeutic drug monitoring of antiarrhythmic drugs. Life Sci J 2007; 4: 1-7
21. Merle L, Laroche ML, Dantoine T, Charmes JP. Predicting and preventing adverse drug reactions in the very old. Drugs Aging 2005; 22: 375-92
22. Field TS, Gurwitz JH, Harrold LR, Rothschild J, DeBellis KR, Seger AC et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc 2004; 52: 1349-54
23. Delafuente JC. Pharmacokinetic and pharmacodynamic alterations in the geriatric patient. Consult Pharm 2008; 23: 324-34
24. Waltman KWS (ed). Preventing Adverse Drug Reactions. Philadelphia: Hanley & Belfus; 2000
25. Catterson ML, Preskorn SH, Martin RL. Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. Psychiatr Clin North Am 1997; 20: 205-18
26. El Desoky ES. Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther 2007; 14: 488-98
27. Abernethy DR. Aging effects on drug disposition and effect. Geriatr Nephrol Urol 1999; 9: 15-19
28. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007; 5: 345-51
29. Weiss BD, Lee JK. Aging: Is your patient taking too many pills? J Fam Pract 2012; 61: 652-61
30. Bressler R, Bahl JJ. Principles of drug therapy for the elderly patient. Mayo Clin Proc 2003; 78: 1564-77
31. Willlams CM. Using medications appropriately in older adults. Am Fam Physician 2002; 66: 1917-24
32. Topinkova E, Baeyens JP, Michel JP, Lang PO. Evidence-based strategies for the optimization of pharmacotherapy in older people. Drugs Aging 2012; 29: 477-94
33. Marcum ZA, Handler SM, Boyce R, Gellad W, Hanlon JT. Medication misadventures in the elderly: A year in review. Am J Geriatr Pharmacother 2010; 8: 77-83
34. Gokula M, Holmes HM. Tools to reduce polypharmacy. Clin Geriatr Med 2012; 28: 323-41
35. Clyne B, Bradley MC, Hughes C, Fahey T, Lapane KL. Electronic prescribing and other forms of technology to reduce inappropriate medication use and polypharmacy in older people: A review of current evidence. Clin Geriatr Med 2012; 28: 301-22
36. Peron EP, Marcum ZA, Boyce R, Hanlon JT, Handler SM. Year in review: Medication mishaps in the elderly. Am J Geriatr Pharmacother 2011; 9: 1-10
37. Marcum ZA, Pugh MJ, Amuan ME, Aspinall SL, Handler SM, Ruby CM et al. Prevalence of potentially preventable unplanned hospitalizations caused by therapeutic failures and adverse drug withdrawal events among older veterans. J Gerontol A Biol Sci Med Sci 2012; 67: 867-74
38. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012; 60: 616-31
39. Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007; 147: 755-65
40. Dettli L. Drug dosage in renal disease. Clin Pharmacokinet 1976; 1: 126-34
41. Denneboom W, Dautzenberg MG, Grol R, De Smet PA. Analysis of polypharmacy in older patients in primary care using a multidisciplinary expert panel. Br J Gen Pract 2006; 56: 504-10
42. Hanlon JT, Aspinall SL, Semla TP, Weisbord SD, Fried LF, Good CB et al. Consensus guidelines for oral dosing of primarily renally cleared medications in older adults. J Am Geriatr Soc 2009; 57: 335-40
43. Hartmann B, Czock D, Keller F. Drug therapy in patients with chronic renal failure. Dtsch Arztebl Int 2010; 107: 647-55; quiz 55-56
44. Peron EP, Gray SL, Hanlon JT. Medication use and functional status decline in older adults: A narrative review. Am J Geriatr Pharmacother 2011; 9: 378-91
45. Berdot S, Bertrand M, Dartigues JF, Fourrier A, Tavernier B, Ritchie K et al. Inappropriate medication use and risk of falls-A prospective study in a large community-dwelling elderly cohort. BMC Geriatr 2009; 9: 30
46. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-97
47. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-310
48. Coleman CI, Limone B, Sobieraj DM, Lee S, Roberts MS, Kaur R et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012; 18: 527-39
49. Zedler BK, Kakad P, Colilla S, Murrelle L, Shah NR. Does packaging with a calendar feature improve adherence to self-Administered medication for long-Term use? A systematic review. Clin Ther 2011; 33: 62-73
50. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006; 58: 521-90
51. Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000; 160: 1612-17
52. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-Anticoagulant effect of warfarin. Blood 2005; 105: 645-49
53. Sandanaraj E, Lal S, Cheung YB, Xiang X, Kong MC, Lee LH et al. VKORC1 diplotype-derived dosing model to explain variability in warfarin dose requirements in Asian patients. Drug Metab Pharmacokinet 2009; 24: 365-75
54. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-64
55. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics 2010; 11: 493-96
56. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis. Lancet 2010; 376: 1312-19
57. Sugunaraj JP, Palaniswamy C, Selvaraj DR, Chaitanya Arudra SK, Sukhija R. Clopidogrel resistance. Am J Ther 2010; 17: 210-15
58. Sibbing D, Gebhard D, Koch W, Braun S, Stegherr J, Morath T et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 2010; 8: 1685-93
59. Ziegler S, Schillinger M, Funk M, Felber K, Exner M, Mlekusch W et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke 2005; 36: 1394-99
60. Harmsze A, van Werkum JW, Bouman HJ, Ruven HJ, Breet NJ, Ten Berg JM et al. Besides CYP2C19 2, the variant allele CYP2C9.3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics 2010; 20: 18-25
61. Staritz P, Kurz K, Stoll M, Giannitsis E, Katus HA, Ivandic BT. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. Int J Cardiol 2009; 133: 341-45
62. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007; 17: 1057-64
63. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: Approaches to the FDA 'boxed warning': A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010; 56: 321-41
64. Sorich MJ, Polasek TM, Wiese MD. Challenges and limitations in the interpretation of systematic reviews: Making sense of clopidogrel and CYP2C19 pharmacogenetics. Clin Pharmacol Ther 2013; 94: 376-82
65. Kawamura M, Ohara S, Koike T, Iijima K, Suzuki H, Kayaba S et al. Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis. J Gastroenterol Hepatol 2007; 22: 222-26
66. Egan LJ, Myhre GM, Mays DC, Dierkhising RA, Kammer PP, Murray JA. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: Variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment Pharmacol Ther 2003; 17: 1521-28
67. Furuta T, Shirai N, Ohashi K, Ishizaki T. Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori. Methods Find Exp Clin Pharmacol 2003; 25: 131-43
68. Kang JM, Kim N, Lee DH, Park YS, Kim JS, Chang IJ et al. Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage. J Gastroenterol Hepatol 2008; 23: 1287-91
69. Kirchheiner J, Muller G, Meineke I, Wernecke KD, Roots I, Brockmoller J. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol 2003; 23: 459-66
70. Ellingrod VL, Schultz SK, Arndt S. Association between cytochrome P4502D6 (CYP2D6)genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score. Psychiatr Genet 2000; 10: 9-11
71. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology (Berl) 1997; 131: 174-79
72. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006; 80: 61-74
73. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23: 9312-18
74. Seripa D, Bizzarro A, Pilotto A, D'Onofrio G, Vecchione G, Gallo AP et al. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease. Pharmacogenet Genomics 2011; 21: 225-30
75. Varsaldi F, Miglio G, Scordo MG, Dahl ML, Villa LM, Biolcati A et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur J Clin Pharmacol 2006; 62: 721-26
76. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H et al. Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386-89
77. Cervilla JA, Rivera M, Molina E, Torres-Gonzalez F, Bellon JA, Moreno B et al. The 5-HTTLPR s/s genotype at the serotonin transporter gene (SLC6A4) increases the risk for depression in a large cohort of primary care attendees: The PREDICT-gene study. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 912-17
78. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-31
79. Gerretsen P, Pollock BG. Pharmacogenetics and the serotonin transporter in late-life depression. Expert Opin Drug Metab Toxicol 2008; 4: 1465-78
80. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66: 2621-24
81. Vladutiu GD, Isackson PJ. SLCO1B1 variants and statin-induced myopathy. N Engl J Med 2009; 360: 304
82. Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 2008; 118: 355-62
83. Utermann G. Apolipoprotein E polymorphism in health and disease. Am Heart J 1987; 113: 433-40
84. Ruiz JG, Array S, Lowenthal DT. Therapeutic drug monitoring in the elderly. Am J Ther 1996; 3: 839-60
85. Ghiculescu R. Therapeutic drug monitoring: Which drugs, why, when and how to do it. Aust Prescr 2008; 31: 42-44
86. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009; 41: 67-76
87. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II). Clin Pharmacokinet 1991; 21: 262-73
88. Lundmark J, Bengtsson F, Nordin C, Reis M, Walinder J. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 2000; 101: 354-59
89. Bonetti A, Franceschi T, Apostoli P, Cetto GL, Recaldin E, Molino A et al. Cisplatin pharmacokinetics in elderly patients. Ther Drug Monit 1994; 16: 477-82
90. Greenblatt DJ, Abernethy DR, Shader RI. Pharmacokinetic aspects of drug therapy in the elderly. Ther Drug Monit 1986; 8: 249-55
91. Waade RB, Molden E, Refsum H, Hermann M. Serum concentrations of antidepressants in the elderly. Ther Drug Monit 2012; 34: 25-30.